SE0202539D0 - Compounds - Google Patents

Compounds

Info

Publication number
SE0202539D0
SE0202539D0 SE0202539A SE0202539A SE0202539D0 SE 0202539 D0 SE0202539 D0 SE 0202539D0 SE 0202539 A SE0202539 A SE 0202539A SE 0202539 A SE0202539 A SE 0202539A SE 0202539 D0 SE0202539 D0 SE 0202539D0
Authority
SE
Sweden
Prior art keywords
compounds
pharmaceutical compositions
therapy
preparing
processes
Prior art date
Application number
SE0202539A
Other languages
English (en)
Swedish (sv)
Inventor
Krister Henriksson
Af Rosenschoeld Magnus Munck
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0202539A priority Critical patent/SE0202539D0/xx
Publication of SE0202539D0 publication Critical patent/SE0202539D0/xx
Priority to TW092122899A priority patent/TWI332500B/zh
Priority to MYPI20033211A priority patent/MY137562A/en
Priority to SI200330661T priority patent/SI1542977T1/sl
Priority to RU2005103617/04A priority patent/RU2326117C2/ru
Priority to PL03375754A priority patent/PL375754A1/xx
Priority to AT03791528T priority patent/ATE348816T1/de
Priority to PCT/SE2003/001328 priority patent/WO2004020415A1/en
Priority to BR0313635-3A priority patent/BR0313635A/pt
Priority to JP2004532506A priority patent/JP2006503019A/ja
Priority to DK03791528T priority patent/DK1542977T3/da
Priority to EP03791528A priority patent/EP1542977B1/de
Priority to CA002495853A priority patent/CA2495853A1/en
Priority to MXPA05002066A priority patent/MXPA05002066A/es
Priority to UAA200501189A priority patent/UA81635C2/ru
Priority to KR1020057003210A priority patent/KR20050059093A/ko
Priority to NZ538443A priority patent/NZ538443A/en
Priority to ES03791528T priority patent/ES2277143T3/es
Priority to CNB038237970A priority patent/CN100398521C/zh
Priority to US10/525,640 priority patent/US7354940B2/en
Priority to AU2003253557A priority patent/AU2003253557B2/en
Priority to DE60310582T priority patent/DE60310582T2/de
Priority to PT03791528T priority patent/PT1542977E/pt
Priority to ARP030103098A priority patent/AR041066A1/es
Priority to ZA200501139A priority patent/ZA200501139B/xx
Priority to IL166826A priority patent/IL166826A/en
Priority to IS7767A priority patent/IS2415B/is
Priority to NO20051540A priority patent/NO20051540L/no
Priority to HK05109053A priority patent/HK1077061A1/xx
Priority to US11/500,207 priority patent/US7662845B2/en
Priority to CY20071100216T priority patent/CY1106027T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
SE0202539A 2002-08-27 2002-08-27 Compounds SE0202539D0 (sv)

Priority Applications (31)

Application Number Priority Date Filing Date Title
SE0202539A SE0202539D0 (sv) 2002-08-27 2002-08-27 Compounds
TW092122899A TWI332500B (en) 2002-08-27 2003-08-20 Novel compounds
MYPI20033211A MY137562A (en) 2002-08-27 2003-08-25 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12
PT03791528T PT1542977E (pt) 2002-08-27 2003-08-26 2,5- dioxoimidazolidin-4-il-acetamidas e análogos como inibidores de metaloproteinase mmp12
UAA200501189A UA81635C2 (en) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12.
NZ538443A NZ538443A (en) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
PL03375754A PL375754A1 (en) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12
AT03791528T ATE348816T1 (de) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-ylacetamide und analoga als inhibitoren von metalloproteinase mmp12
PCT/SE2003/001328 WO2004020415A1 (en) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12.
BR0313635-3A BR0313635A (pt) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-5-il acetamidas e análogos como inibidores da metaloproteinase mmp12
JP2004532506A JP2006503019A (ja) 2002-08-27 2003-08-26 メタロプロテイナーゼｍｍｐ１２のインヒビターとしての２，５−ジオキソイミダゾリジン−４−イルアセトアミドおよび類似体
DK03791528T DK1542977T3 (da) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-ylacetamider og analoger som inhibitorer af metalloproteinase MMP12
EP03791528A EP1542977B1 (de) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-ylacetamide und analoga als inhibitoren von metalloproteinase mmp12
CA002495853A CA2495853A1 (en) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12
MXPA05002066A MXPA05002066A (es) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-il acetamidas y analogos como inhibidores de la metaloproteinasa mmp12.
SI200330661T SI1542977T1 (sl) 2002-08-27 2003-08-26 2,5-dioksoimidazolidin-4-il acetamidi in analogi kot inhibitorji metaloproteinaze MMP12
KR1020057003210A KR20050059093A (ko) 2002-08-27 2003-08-26 메탈로프로테이나제 ｍｍｐ12의 억제제로서의 2,5-디옥소이미다졸리딘-4-일 아세트아미드 및 동족체
RU2005103617/04A RU2326117C2 (ru) 2002-08-27 2003-08-26 2, 5-диоксоимидазолидин-4-ил-метилкарбонильные соединения, способ их получения, содержащая их фармацевтическая композиция и их применение в изготовлении лекарственного средства
ES03791528T ES2277143T3 (es) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-ilacetamidas y analogos como inhibidores de metaloproteinasa mmp12.
CNB038237970A CN100398521C (zh) 2002-08-27 2003-08-26 作为金属蛋白酶mmp12抑制剂的2,5-二氧代咪唑烷-4-基乙酰胺及类似物
US10/525,640 US7354940B2 (en) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12
AU2003253557A AU2003253557B2 (en) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
DE60310582T DE60310582T2 (de) 2002-08-27 2003-08-26 2,5-dioxoimidazolidin-4-ylacetamide und analoga als inhibitoren von metalloproteinase mmp12
ARP030103098A AR041066A1 (es) 2002-08-27 2003-08-27 2,5-dioxoimidazolidin-4-il-acetamidas y analogos como inhibidores de la metaloproteinasa mmp12
ZA200501139A ZA200501139B (en) 2002-08-27 2005-02-08 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
IL166826A IL166826A (en) 2002-08-27 2005-02-10 2,5 - dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12
IS7767A IS2415B (is) 2002-08-27 2005-03-22 2,5-díoxóimídasólídín-4-ýl asetamíð og hliðstæð efni sem tálmar málmpróteinasa MMP12
NO20051540A NO20051540L (no) 2002-08-27 2005-03-23 2,5-dioksoimidazolidin-4-yl acetamider og analoger som inhibitorer av metalloproteinas MMP12
HK05109053A HK1077061A1 (en) 2002-08-27 2005-10-13 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors or metalloproteinase mmp12
US11/500,207 US7662845B2 (en) 2002-08-27 2006-08-07 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
CY20071100216T CY1106027T1 (el) 2002-08-27 2007-02-16 2,5-διοξοϊμιδαζολιδιν-4-υλ ακεταμιδια και αναλογα ως αναστολεις μεταλλοπρωτεϊνασης μμρ12

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202539A SE0202539D0 (sv) 2002-08-27 2002-08-27 Compounds

Publications (1)

Publication Number Publication Date
SE0202539D0 true SE0202539D0 (sv) 2002-08-27

Family

ID=20288820

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202539A SE0202539D0 (sv) 2002-08-27 2002-08-27 Compounds

Country Status (29)

Country Link
US (2) US7354940B2 (de)
EP (1) EP1542977B1 (de)
JP (1) JP2006503019A (de)
KR (1) KR20050059093A (de)
CN (1) CN100398521C (de)
AR (1) AR041066A1 (de)
AT (1) ATE348816T1 (de)
AU (1) AU2003253557B2 (de)
BR (1) BR0313635A (de)
CA (1) CA2495853A1 (de)
CY (1) CY1106027T1 (de)
DE (1) DE60310582T2 (de)
DK (1) DK1542977T3 (de)
ES (1) ES2277143T3 (de)
HK (1) HK1077061A1 (de)
IL (1) IL166826A (de)
IS (1) IS2415B (de)
MX (1) MXPA05002066A (de)
MY (1) MY137562A (de)
NO (1) NO20051540L (de)
NZ (1) NZ538443A (de)
PL (1) PL375754A1 (de)
PT (1) PT1542977E (de)
RU (1) RU2326117C2 (de)
SE (1) SE0202539D0 (de)
TW (1) TWI332500B (de)
UA (1) UA81635C2 (de)
WO (1) WO2004020415A1 (de)
ZA (1) ZA200501139B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
ITRE20010042A1 (it) * 2001-04-24 2002-10-24 Corghi Spa Dispositivo sollevatore per macchine smontagomme
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US6979750B1 (en) 2003-04-18 2005-12-27 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US7321065B2 (en) 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
ATE508744T1 (de) 2004-08-19 2011-05-15 Quest Pharmaceutical Services 5-ä3-(4-benzyloxyphenylthio)-fur-2-ylü- imidazolidin-2, 4-dion und analoga als hemmer der makrophagenelastase
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
EP2096107A1 (de) 2004-12-23 2009-09-02 GPC Biotech AG Derivate von Quadratsäure mit Wirkung gegen Proliferation
US7945626B2 (en) * 2005-03-16 2011-05-17 M&Fc Holding, Llc Method, system, apparatus, and computer program product for determining a physical location of a sensor
WO2007084486A2 (en) * 2006-01-13 2007-07-26 Battelle Memorial Institute Animal model for assessing copd-related diseases
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
ATE540932T1 (de) * 2006-08-31 2012-01-15 Schering Corp Hydantoin-derivate als antibakterielle wirkstoffe
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
CN101024619B (zh) * 2007-03-29 2010-12-01 上海大学 N-取代邻溴苄酰胺的合成方法
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2361242B1 (de) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidaseinhibitoren und deren verwendung
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
FR2944525B1 (fr) * 2009-04-17 2011-06-24 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
EP2480528B1 (de) 2009-09-25 2018-08-29 Oryzon Genomics, S.A. Lysinspezifische demethylase-1-inhibitoren und ihre verwendung
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
MX2012012111A (es) 2010-04-19 2013-05-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especifica de lisina y su uso.
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
JP6054868B2 (ja) 2010-07-29 2016-12-27 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． Ｌｓｄ１のアリールシクロプロピルアミンをベースとしたデメチラーゼ阻害剤およびそれらの医学的使用
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (de) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysindemethylase-hemmer für myeloproliferative erkrankungen
EP2741741A2 (de) * 2011-05-19 2014-06-18 Oryzon Genomics, S.A. Lysindemethylaseinhibitoren zur entzündungserkrankungen oder -zustände
US20140296255A1 (en) * 2011-05-19 2014-10-02 Oryzong Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
CN104203914B (zh) 2011-10-20 2017-07-11 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
WO2014051538A1 (en) * 2012-09-25 2014-04-03 Empire Technology Development Llc Oxidizing agents on pigments
AR092971A1 (es) * 2012-10-26 2015-05-06 Lilly Co Eli Inhibidores de agrecanasa
CN103588758A (zh) * 2013-11-04 2014-02-19 南京大学 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用
EP2907512A1 (de) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Hemmer von MMP-12 als antivirale Wirkstoffe
CN104030930B (zh) * 2014-06-20 2016-02-24 河北序能生物技术有限公司 一种反式-（1r,2s）-2-（3,4-二氟苯基）环丙胺盐酸盐的合成方法
US11739080B2 (en) 2018-05-15 2023-08-29 Foresee Pharmaceuticals Usa, Inc. Matrix metalloproteinase (MMP) inhibitors and methods of use thereof
CN112755023B (zh) * 2021-01-22 2023-04-25 湖南师范大学 一种新型表观遗传因子抑制剂2800z在制备肝癌药物中的应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2327890A (en) 1940-04-17 1943-08-24 Parke Davis & Co Substituted phenoxyalkyl ethers
US2745875A (en) 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
US3849574A (en) 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS6172762A (ja) 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
JPS61212292A (ja) 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
GB8618559D0 (en) 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
US4983771A (en) 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
PH31245A (en) 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NL9201230A (nl) 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
EP0640594A1 (de) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoinderivat als Metalloproteaseinhibitor
JPH07105549A (ja) 1993-09-30 1995-04-21 Canon Inc 光学的情報記録再生方法及び光学的情報記録再生装置
CA2174650A1 (en) 1993-11-16 1995-05-26 Mark G. Bock Piperidinyl camphorsulfonyl oxytocin antagonists
EP0709375B1 (de) 1994-10-25 2005-05-18 AstraZeneca AB Therapeutisch wirksame Heterocyclen
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
KR19990067687A (ko) 1995-11-22 1999-08-25 마르크 젠너 이미다졸 치환체를 갖는 메캅토알킬펩티딜 화합물 및 매트릭스금속단백질 가수분해 효소의 억제제 및/또는 종양 괴사 인자로서의 용도
GB9616643D0 (en) 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
JP2001503400A (ja) 1996-10-22 2001-03-13 ファルマシア・アンド・アップジョン・カンパニー マトリックス・メタロプロテイナーゼ阻害剤としてのα―アミノスルホニルヒドロキサム酸類
HUP0003362A3 (en) 1997-05-06 2001-04-28 Novo Nordisk As Piperidine derivatives and pharmaceutical compositions containing them
EP0877019B1 (de) 1997-05-09 2001-12-12 Hoechst Aktiengesellschaft Substituierte Diaminocarbonsäuren
WO1999006361A2 (en) 1997-07-31 1999-02-11 Abbott Laboratories N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
WO1999024399A1 (en) 1997-11-12 1999-05-20 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
HUP0101176A3 (en) 1998-02-04 2002-06-28 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AU4074799A (en) 1998-05-14 1999-11-29 Du Pont Pharmaceuticals Company Substituted aryl hydroxamic acids as metalloproteinase inhibitors
SK18302000A3 (sk) 1998-06-03 2001-06-11 Gpi Nil Holdings, Inc. N-viazané sulfónamidy n-heterocyklických karboxylových kyselín a izosterov karboxylových kyselín, farmaceutický prostriedok s ich obsahom a ich použitie
EP1087937A1 (de) 1998-06-17 2001-04-04 Du Pont Pharmaceuticals Company Cyclische hydroxamsäuren als metalloproteinase-inhibitoren
FR2782082B3 (fr) 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
WO2000012477A1 (en) 1998-08-29 2000-03-09 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as proteinase inhibitors
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
CA2346288A1 (en) 1998-10-07 2000-04-13 Yazaki Corporation Sol-gel process using porous mold
ATE260255T1 (de) 1998-11-05 2004-03-15 Pfizer Prod Inc 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
EP1140859A2 (de) * 1998-12-18 2001-10-10 Axys Pharmaceuticals, Inc. (hetero)aryl-bizyklische heteroaryl derivate, deren herstellung und deren verwendung als protease inhibitoren
EP1150975A1 (de) 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepanderivate nützlich als mmp-12 inhibitoren
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
PL349354A1 (en) 1999-01-28 2002-07-15 Chugai Pharmaceutical Co Ltd Substituted phenethylamine derivatives
US6294694B1 (en) 1999-06-04 2001-09-25 Wisconsin Alumni Research Foundation Matrix metalloproteinase inhibitors and method of using same
GB9916562D0 (en) 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US20020006920A1 (en) 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
US6266453B1 (en) 1999-07-26 2001-07-24 Computerized Medical Systems, Inc. Automated image fusion/alignment system and method
EP1078923B1 (de) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Benzothiophen-Derivaten
AP2002002442A0 (en) 1999-08-12 2002-03-31 Pharmacia Italia Spa 3(5)-Amino-pyrazole derivatives, process for their preparation and their preparation and their use as antitumor agents.
SE9904044D0 (sv) * 1999-11-09 1999-11-09 Astra Ab Compounds
NO313680B1 (no) * 2000-07-17 2002-11-11 Ericsson Telefon Ab L M Informasjonsarrangement i SDH- og SONET-nettverk
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
EP1325903A4 (de) 2000-08-11 2005-07-27 Kaken Pharma Co Ltd 2,3-diphenylpropionsäurederivate oder deren salze, medikamente oder zelladhäsionshemmer, die diese enthalten und deren verwendung
US20020065219A1 (en) 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
US20020091107A1 (en) 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
WO2002020515A1 (en) 2000-09-08 2002-03-14 Abbott Laboratories Oxazolidinone antibacterial agents
EP1191024A1 (de) 2000-09-22 2002-03-27 Harald Tschesche Thiadiazine und ihre Verwendung als Metallproteinaseinhibotoren
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2004527511A (ja) 2001-03-15 2004-09-09 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼ阻害剤
WO2002096426A1 (en) 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
EP1550725A4 (de) 2002-06-05 2010-08-25 Kaneka Corp Verfahren zur herstellung eines optisch aktiven a-methylcystein-derivats
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202692D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
SE0202693D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221246D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221250D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US20040266832A1 (en) 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine
TWI220073B (en) 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
SE0401763D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
DK1542977T3 (da) 2007-03-19
ZA200501139B (en) 2006-12-27
KR20050059093A (ko) 2005-06-17
BR0313635A (pt) 2005-06-21
IL166826A (en) 2009-06-15
CN100398521C (zh) 2008-07-02
IS2415B (is) 2008-10-15
WO2004020415A1 (en) 2004-03-11
CY1106027T1 (el) 2011-04-06
CA2495853A1 (en) 2004-03-11
ES2277143T3 (es) 2007-07-01
AU2003253557A1 (en) 2004-03-19
AR041066A1 (es) 2005-04-27
RU2326117C2 (ru) 2008-06-10
JP2006503019A (ja) 2006-01-26
MY137562A (en) 2009-02-27
EP1542977A1 (de) 2005-06-22
DE60310582T2 (de) 2007-11-22
US20050245586A1 (en) 2005-11-03
HK1077061A1 (en) 2006-02-03
MXPA05002066A (es) 2005-06-08
ATE348816T1 (de) 2007-01-15
CN1688550A (zh) 2005-10-26
US7662845B2 (en) 2010-02-16
NO20051540L (no) 2005-03-23
UA81635C2 (en) 2008-01-25
PL375754A1 (en) 2005-12-12
TWI332500B (en) 2010-11-01
PT1542977E (pt) 2007-02-28
TW200407313A (en) 2004-05-16
DE60310582D1 (de) 2007-02-01
NZ538443A (en) 2006-09-29
RU2005103617A (ru) 2006-01-10
US20060276524A1 (en) 2006-12-07
EP1542977B1 (de) 2006-12-20
IS7767A (is) 2005-03-22
US7354940B2 (en) 2008-04-08
AU2003253557B2 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
SE0202539D0 (sv) Compounds
SE0104140D0 (sv) Novel Compounds
SE0200920D0 (sv) Novel compounds
SE0302811D0 (sv) Novel compounds
SE0300480D0 (sv) Novel compounds
SE0301700D0 (sv) Novel compounds
TW200800999A (en) Novel compounds
TW200616995A (en) Novel compounds
DE602004021472D1 (en) Pyrimiidinverbindungen
TW200801003A (en) Novel compounds
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
MXPA02012425A (es) Compuestos nuevos.
TW200613243A (en) Novel compounds
MY128924A (en) Novel compounds
SE0202133D0 (sv) Novel compounds
AU2003228770A8 (en) Substituted pyrazolopyrimidines
TW200635917A (en) Novel compounds
TW200605888A (en) Novel compounds
TW200639156A (en) New compounds
TW200626553A (en) Novel compounds
TW200738659A (en) Novel compounds
SE0302139D0 (sv) Novel compounds
TW200635916A (en) Compounds
SE0302192D0 (sv) Novel compounds
TW200740781A (en) Novel compounds